Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Belatacept to Prevent Organ Rejection in Kidney Transplant Patients (BESTT)
This study is ongoing, but not recruiting participants.
Study NCT00346151 Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
First Received: June 27, 2006 Last Updated: May 13, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Transplantation, Kidney
End-Stage Renal Disease
Additional conditions recognized in this trial
Kidney Diseases
Kidney Failure, Chronic
More general conditions related to this trial
Kidney Failure
Renal Insufficiency
Renal Insufficiency, Chronic
Urologic Diseases
Interventions listed in this trial
Belatacept
Sirolimus
Anti-thymocyte globulin
methylprednisolone
Additional drug interventions recognized in this trial
Abatacept
Antilymphocyte Serum
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Anti-Inflammatory Agents
Antibiotics, Antineoplastic
Antiemetics
Antifungal Agents
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Antirheumatic Agents
Autonomic Agents
Central Nervous System Agents
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents
Neuroprotective Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Sponsors listed in this trial
National Institute of Allergy and Infectious Diseases (NIAID)
Immune Tolerance Network
Back to top of Main Content
